A B S T R A C T To study the effect of kallikrein on renal renin release, we superfused rat renal cortical slices with 3.5 to 140 milliesterase units (mEU)/ml of purified rat urinary kallikrein. Kallikrein was a potent stimulus of renin release. Renin rose in a dosedependent fashion from 70 mEU/ml to 140 mEU/ml. The response to 140 mEU/ml was greater than that seen with maximal doses of prostaglandin E2 (170+43%, P < 0.05) and at least the same as isoproterenol (242+49% increase), or dibutyryl cyclic AMP (272+±40%). Trypsin was ineffective under these experimental conditions. Kallikrein-stimulated renin release was completely abolished by trasylol, whereas bradykinin did not increase renin production, indicating that kallikrein's effect is not mediated via kinin generation. There was no demonstrable acid activation or kallikrein activation of the superfusate and chromatography on Sephacryl S-200 revealed a single renin peak of -40,000 mol wt, suggesting that all of the renin release was in the active form. The data suggests that urinary kallikrein acts directly on the rat kidney to release renin, possibly via proteolytic conversion of prorenin to active renin. Our results support the concept that kallikrein may be an endogenous activator of prorenin in the kidney.
INTRODUCTION
Both the renin-angiotensin system and the kallikreinkinin system have been implicated in the control of sodium and water excretion, blood pressure regulation, and renal hemodynamics.
These two systems are interrelated in that renal kallikrein, via kinin generation, stimulates the production of prostaglandin (1, 2) , which in turn, increases renin release (3) (4) (5) . Furthermore, recently Sealey et al. (6) have reported that human urinary kallikrein converts plasma inactive renin to active renin. Because renal kallikrein is produced in the renal cortex (7) (8) (9) , especially in tubular cells (9, 10) , it has been proposed that kallikrein may be the endogenous renin activator in the kidney. Direct action of renin stimulation by kallikrein has not been reported. The present study was carried out to evaluate the role of renal kallikrein on renin release.
METHODS
Isolation of rat urinary kallikrein. The isolation of rat urinary kallikrein (RUK)' was based on the report of Nu.stad and Pierce (11) . A 24-h urine collection was made from 50 female Sprague-Dawley rats, and dialyzed against distilled water at 4°C for 2 d. It was then lyophilized, resuspended in 9 ml of potassium phosphate buffer, pH 7.4, containing 0.2 M KC1, and applied to a DEAE-Sephadex coluimn from each of the 6-ml fractions were assayed for a-N-Ptosyl-L-arginine methyl ester (TAME) esterase activity. After the DEAE-Sephadex column chromatography, the active kallikrein fractions were pooled, dialyzed against distilled water at 4°C for 24 h, lyophilized, and resuspended in 2 ml of 0.05 M Tris-Cl buffer, pH 8.0, containing 0.05 M NaCl and 0.2% NaN3. This sample was applied to a Sephacryl S-200 column (1.5 x 90 cm; void volume 56.7 ml). The column was eluted with 0.05 M Tris-Cl buffer, pH 8.0, which also contained 0.05 M NaCl and 0.2% NaN3 at a flow rate of 10 ml/h. 2-ml fractions were collected and assayed for TAME esterase activity.
Kallikrein assay. Esterolytic activity of the kallikrein fraction was measured using the proteinase substrate HCI TAME. The unhydrolyzed ester was measured by the Roberts colorimetric method (12) .
Kininogenase assays. Urinary kallikrein samples that had been isolated from rat urine were also assayed for kininogenase activity by the method of Nustad et al. (13) . Dog plasma was used as a source of kininogen. A 250-ml sample of dog blood was collected into 100 ml of 1.32% sodium citrate. The plasma was separated by centrifugation, heated by 60°C for 30 min, 'Abbreviations used in this paper: KRBG, Krebs-Ringer bicarbonate glucose buffer; mEU, milliesterase units; RUK, rat urinary kallikrein; TAME, a-N-P-tosyl-L-arginine methyl ester. and dialyzed extensively against distilled water at 4°C. The dog plasma preparation at a dilution of 1:2 was incubated with each kallikrein test samples at 30°C for 3 min. The kinin generated was then bioassayed by adding an aliquot of the mixture, exactly at the end of the incubation time, to a rat uterus in a muscle chamber containing modified Krebs bicarbonate media (de Jalon solution), gassed with 95% 02, 5% CO2, and the uterine contractile response was measured by glass transducer FTO3 and recorded in a physiograph recorder (Hewlett-Packard 7702B, Hewlett-Packard Co., Palo Alto, Calif.). The preparation was standardized with synthetic bradykinin and the results were expressed in terms of micrograms of bradykinin generated per minute.
Superfusion of rat renal cortical slices. Sprague-Dawley female rats weighing 200-250 g were used for the experiments. The rats were maintained on a regular Purina Rat Chow diet (Ralston Purina Co., St. Louis, Mo.) and were anesthetized with sodium pentobarbital (50 mg/kg i.p.), and decapitated. The kidneys were quickly removed, decapsulated, and placed in a Stadie-Riggs microtome. One renal cortical slice, -0.3-0.5 mm in thickness, was obtained from the ventral and another from the dorsal surface of each kidney. 60-80 mg (-1.5 slices) of renal cortical tissue was placed in the middle of two 0-ring joints that contained a small plastic filter in one side to prevent displacement ofthe tissue after the superfusion was started. The two 0-ring joints were held together by a clamp and the two ends of it were connected with polyethylene tubing (PE 280) with an interior diameter of2.15 mm. The tissue holder was placed in a water bath at 37°C and the tissue was perfused with Krebs-Ringer bicarbonate, glucose buffer (KRBG), pH 7.4, containing Na+, 144 mM; K+, 4.7 mM; Ca++, 2.7 mM; Cl-, HCO-, 25 mM; Mg++, 1.2 mM; H2PO4, 1.2 mM; glucose, 11 mM, which is continuously bubbled with a mixture of 95%02 and 5% CO2. The polyethylene tubing passed through a peristaltic pump. The tubing was connected to a warming coil and a debubbler before reaching the tissue. The efferent end of the tubing was connected to a fraction collector. The dead space of the whole system was -10 ml and the flow rate was 1 ml/min. The initial 75 min of superfusion with KRBG were discarded.
After a 60-min perfusion to obtain a stable base line, a control sample was collected over a 20-min period (period 1) (Fig. 3) . The stimulating agent was dissolved in 30 ml of KRBG and superfused over 30 min. The experimental sample was collected during the last 20 min after application of the stimulus (period 2). The superfusate was changed to the control KRBG and the next control sample was obtained during the last 20 min of the 30-min control superfusate (period 3).
The above schedule was repeated two to three times. Experiments were performed with 3.5-140 mEU/ml of RUK, 0.1 uM-0.1 mM of bradykinin (Sigma Chemical Co., St. Louis, Mo.), 1 nM-6 uM (23 to 138 x 103 mEU/ml) of trypsin, 472 kallikrein inhibiting units/ml (KIU/ml) of trasylol, 0.8 ,uM of isoproterenol, 5 mM of dibutyryl cyclic AMP (all from Sigma Chemical Co.), and 0.1 mM of prostaglandin E2 (Upjohn Co., Kalamazoo, Mich.). Separate tissues were superfused with each stimulus and replicated experiments (n = 4) were performed. To investigate the possibility of tissue damage by kallikrein, the enzymes glutamic oxaloacetic transaminase and y-glutamyl transpeptidase were measured in control and kallikrein-stimulated samples by previously described methods (14, 15 5 ,p1 of 8-hydroxyquinoline. Incubation was for 3 h at 37°C after which samples were transferred to an ice bath, 50-Al aliquots were taken for radioimmunoassay of generated angiotensin I (Becton, Dickinson Co., Renin Kit). The interassay coefficient of variation using superfusate samples was 11.5% (n = 10) and the intraassay coefficient of variation was 10.5% (n = 10). The recovery of angiotensin I added to superfusate was 85±2% (n = 10). To rule out the presence of other serine proteases active at neutral pH, the same kallikrein-stimulated samples and control samples were assayed in the presence and absence of 5 plI of the serine protease inhibitor, phenylmethyl sulfonylfluoride (5% in ethanol). There was no significant difference in angiotensin I generation by the addition of phenylmethyl sulfonylfluoride (r = 0.98, P < 0.01, n = 10). Therefore, we did not use phenylmethyl sulfonylfluoride in the experiments. The results of the experiments are expressed as the percentage increase over the base-line renin release after each stimulation. Statistical analysis was performed using the paired t test with log transformation. Significance was defined as P value of <0.05. To rule out that the increased renin concentration in the kallikrein superfused samples was due to activation of inactive renin, present in the nephrectomized plasma by kallikrein, the samples were incubated with synthetic tetradecapeptide (50 ng/tube, Boehringer Mannheim Biochemicals, Indianapolis, Ind.) instead of nephrectomized rat plasma.
Acid activation of renin. 1-ml sample of superfusate or rat plasma was dialyzed for 24 h at 4°C against glycine-HCl buffer at pH 3.3, then dialyzed against sodium phosphate buffer at pH 7.4 for a further 24 h. Renin concentration was then measured as described in the preceding section.
Determination of molecular weight of renin. 10 ml of superfusion sample was lyophilized and resuspended in 1 ml of 0.05 M Tris-chloride buffer, pH 8.0, which also contained 0.05 M HaCl and 0.2% NaN3, and was applied to a Sephacryl S-200 column (1.5 x 90 cm; void volume 56.7 ml). The column was eluted with 0.05 M Tris-chloride buffer, pH 8.0, which also contained 0.05 M NaCl and 0.2% NaN3. 1-ml fractions were collected and assayed for angiotensin I generating activity. This column was calibrated with bovine serum albumin (67,000 mol wt), ovalbumin (45,000 mol wt), chymotrypsinogen A (25,000 mol wt), and cytochrome C (12,400 mol wt). A plot of the ratio of the elution volume/void volume (Ve/Vo) vs. the log ofmolecular weight ofthe standards generated a straight line for estimation ofthe molecular weight of renin. Fig. 1 shows the elution of TAME esterase activity after DEAE-Sephadex column chromatography. Two peaks, A and B, of esterase activity are present and the B component is RUK (11 2 Effect of kallikrein on renin release. Effect of RUK (3.5 to 140 mEU/ml) on renin release from rat renal cortical slices was evaluated. 70 to 140 mEU/ml of RUK-stimulated the renin release significantly in a dose-dependent fashion.
RESULTS
The percent increase is shown on the ordinate and the dlose of kallikrein is shown in a log plot on the abscissa. any significant increase of renin concentration as compared with control superfusate. To test the possibility that kallikrein (or some enzyme released from the kidney tissue) might be activating inactive renin in the nephrectomized rat plasma during the renin assay, we used the synthetic tetradecapeptide as the source of angiotensinogen. When the renin assay ofthe kallikreinstimulated samples was performed using tetradecapeptide instead of nephrectomized rat plasma in the same sample, there was no significant difference in the percent increase of renin release (RUK 140 mEU/ml and nephrectomized rat plasma caused 483±65% increase, and RUK 140 mEU/ml + tetradecapeptide, 50 ng/tube caused 411+81% increase). Therefore, kallikrein must be acting directly on renal tissue to release renin. Furthermore, nephrectomized rat plasma had no detectable renin activity and was also not activated by acid treatment and subsequent incubation with 140 mEU/ml of RUK for 1 h at 25°C. Fig. 4 shows the effects of trasylol on renin release. 120 mEU/ml of RUK increased the renin release by 172.2±72.4% and inhibition of this increase occurred with 472 kallikrein inhibiting units/ml of trasylol. RUK was more potent than maximal stimulating doses of prostaglandin E2 (0.1 mM) which caused a percentage increase of renin release of(170+43%, n = 4) and equal or more potent than 5 mM dibutyryl cyclic AMP (272+40%, n = 4) or 0.8 ,uM isoproterenol (242±49%, n = 4), but the data were not significantly different.
Because kallikrein can generate bradykinin and bradykinin stimulate prostaglandin production, which in turn can stimulate renin release, the effect of bradykinin on renin release from rat renal cortical slices was evaluated (Fig. 5) . Doses of bradykinin from 0.1 AM to 0.1 mM did not stimulate renin release. Sephacryl column chromatography ofbasal and kallikrein-stimulated samples showed only one broad peak of angiotensin I generating activity (Fig. 7) . The apex of this fraction was fraction 91, which corresponded to molecular weight, -40,000, using the calibration curve in Fig. 8 . There were no significant differences in the elution profile between basal and kallikrein-stimulated renin samples. form (16, 17) . This prorenin is mainly of molecular weight of 60,000. However, other large molecular weight renins are also present. In man, both high and low molecular weight renin are secreted. In human plasma, the conversion of inactive renin to active renin has been accomplished by acid (18, 19) , trypsin (20) , or cold (21, 22) treatment of plasma, and more recently by the addition of the proteolytic enzyme kallikrein (6, 23) . Furthermore, Inagami et al. (24, 25) has reported the activation of purified high molecular weight renin of plasma and kidney by kallikrein. It is still controversial whether the activation of inactive (high molecular weight) plasma renin converts the inactive renin to the low molecular weight renin. In view of the fact that kallikrein can activate renin, the suggestioin (10) . Furthermore, a similar role for kallikrein in conversion of proinsulin within the beta cell of the pancreas has been proposed (26, 27 Furthermore, Sephacryl S-200 column chromatography of the superfusate from basal and kallikrein-stimulated samples revealed only one peak of active renin, -40,000 mol wt. Inagami et al. (16) reported that rat kidneys contain high molecular weight renin that is readily converted to the low molecular weight renin by renal proteases. Kallikrein is a potent stimulator of renin release since the response to kallikrein was significantly greater than that of prostaglandin E2 and equal to or greater than the response to dibutyryl cyclic AMP and isoproterenol. Our data, therefore, support the hypothesis that kallikrein may play a role in the secretion of renin. The precise mechanism by which the superfused kallikrein stimulated renin release is not elucidated by our data. Possibly kallikrein enters the juxtaglomerular cells by pinocytosis and activates the secretory process and conversion of high molecular weight renin to low molecular weight renin or possibly it affects the cell membrane and release renin from those granules that have fused with the cell membrane in the process of secretion.
